|
|
|
|
|
|
by s1artibartfast
3 hours ago
|
|
|
Third party private healthcare decisions are almost non-existant in the US due to the payment systems. People are on the hook for the decisions of others either through their premium, taxes, or both. Of course, this is non-central and rarely the concern people present. That said, 2026 US GLP-1 healthcare sales projections run between 60 and 100 billion [1]. it will be interesting to see if these miricle drugs can really provide that much benefit/offset that much cost. For comparison, Medicare part D is ~150 billion in its entirety.
https://evolvancemarketresearch.com/reports/glp-1-weight-los... |
|
|
The payment part is almost entirely pushing against GLP-1 agonists. Nobody has a long-term financial stake in patient costs to care that lifetime costs will likely be lower; insurers are just looking at the next couple years against expected churn. Another cost of tying health insurance to employment.